DeutschNewstral
Article
Bbarrons.com on 2021-08-26 17:54
Early Sales of Biogen's Alzheimer Drug Remain Unclear3 min read
Related news
- BMedicare Will Limit Coverage of Biogen's Alzheimer's Drug2 min readbarrons.com
- BBiogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.3 min readbarrons.com
- BFDA Narrows Its Label on Biogen's Alzheimer's Drug a Month After Approving It3 min readbarrons.com
- MGoogle earnings top estimates as online ad sales remain resilient2 min readmarketwatch.com
- BMcDonald's Price Increases Boost Sales. Inflation to Remain an Issue.1 min readbarrons.com
- BBiogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug2 min readbarrons.com
- BFDA Approves Eisai and Biogen's New Alzheimer's Therapy 1 min readbarrons.com
- BAcknowledging Concerns Over Biogen's Alzheimer's Drug, FDA Asks for Investigation2 min readbarrons.com
- BRetail Sales Slowed More Than Expected in July. Still, Consumers Remain Flush.3 min readbarrons.com
- MTilray expected to grow sales sequentially but remain in the red3 min readmarketwatch.com
- BBiogen's Aduhelm Struggles Don't Hurt Lilly's Outlook, Says Analyst3 min readbarrons.com
- BBiogen's CEO Didn't Mention an Impending FDA Decision, Sending the Stock Down4 min readbarrons.com
- BBiogen's New Alzheimer's Drug Faces Its Next Test. 4 Big Questions.4 min readbarrons.com
- BTop FDA Staffers Defend Approval of Biogen's Alzheimer's Drug 4 min readbarrons.com
- BBiogen's Alzheimer's Drug Has a Shot at Redemption. Will It Be Enough?5 min readbarrons.com
- MFDA calls for investigation into its own approval of Biogen's Alzheimer's drug2 min readmarketwatch.com
- BBiogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path3 min readbarrons.com
- MBiogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says3 min readmarketwatch.com
- BBiogen's ALS Drug Will Get FDA Review. It's a Long Shot for the Stock.3 min readbarrons.com